Small-molecule inhibitors, including brusatol, ML358, K-563, and AEM1, which directly or indirectly target NRF2 or its downstream signaling, inhibit tumor growth and enhance the antitumor activity of chemotherapeutic agents in multiple cancer models [18–23]. Here, NFE2L2 is linked to neoplasm.